Submit to Special Issue Submit Abstract to Special Issue Review for Brain Sciences Edit a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Special Issue "New Insights in Psychiatric Disorder Psychopharmacology"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Psychiatric Diseases".

Deadline for manuscript submissions: 30 June 2023 | Viewed by 8876

Share This Special Issue

Special Issue Editors

Dr. Laura Orsolini

E-Mail Website
Guest Editor

Unit of Clinical Psychiatry, Department of Neurosciences/DIMSC, Polytechnic University of Marche, 60126 Ancona, Italy
Interests: digital psychiatry; digital phenotyping; youth mental health; web-based psychopathology; techno-addictions; behavioural addictions; gaming disorder; internet addiction; social media addiction; eating disorders; youth psychopathology
Special Issues, Collections and Topics in MDPI journals

Dr. Mohammadreza Shalbafan

E-Mail Website
Co-Guest Editor

School of Medicine (IUMS), Tehran, Iran
Interests: psychopharmacology; neuropsychopharmacology; clinical psychiatry; mental illness; treatment; psychoeducation; clinical neuroscience; psychological assessment; rehabilitation psychology and psychiatry; therapeutic outcomes

Special Issue Information

Dear Colleagues,

The development of a plethora of new therapeutic psychopharmacological targets as well as advances in the clinical and research in the field of psychopharmacology has allowed the implementation of new research trajectories and facilitated advances toward a more personalized and patient-tailored psychopharmacology.

In this Special Issue, preclinical and clinical studies specifically focusing on new insights and recent advances in psychopharmacology are welcome, including safety, tolerability, efficacy studies, focusing on special populations (e.g., pregnant and/or breastfed women, the elderly, youths) as well as studies coming from the real-world clinical experiences (e.g., case report, case series, and naturalistic observational studies), meta-analyses, and systematic reviews in the field.

Dr. Laura Orsolini
Dr. Mohammadreza Shalbafan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

psychopharmacology
psychiatry psychopharmacology
youth psychopharmacology
new treatment targets in psychiatry
personalized psychiatry

Published Papers (5 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review, Other

Open AccessArticle

Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study

Renato de Filippis

Filippo Antonio Staltari

Cristina Segura-Garcia

and

Pasquale De Fazio

Brain Sci. 2023, 13(4), 577; https://doi.org/10.3390/brainsci13040577 - 29 Mar 2023

Viewed by 649

Abstract

We hypothesized that shifting from oral second-generation antipsychotics (SGA) to their long-acting injectable (LAI) counterpart would be beneficial for the psychopathological, cognitive, social, and general health domains in outpatients suffering from schizophrenia. We aimed to evaluate the prospective usefulness of SGA-LAI treatment by carrying out a head-to-head comparison of two different medications (i.e., aripiprazole monohydrate (Ari-LAI) and paliperidone palmitate 1 and 3 month (PP1M, PP3M)) in a real-world setting, assessing the effectiveness and tolerability of Ari-LAI and PP1M/PP3M over a 15 month follow-up. A total of 69 consecutive individuals affected by schizophrenia were screened for eligibility. Finally, 46 outpatients (29 treated with Ari-LAI, 13 with PP1M, and four with PP3M) were evaluated through clinical, functional, and neuropsychological assessment administrated at baseline and after 3-, 12-, and 15-month follow-up periods. Moreover, periodic general medical evaluations were carried out. We estimated an overall improvement over time on the explored outcomes, without differences with respect to the type of LAI investigated, and with a global 16.4% dropout rate. Our findings suggest that switching from oral SGA to SGA-LAIs represents a valid and effective treatment strategy, with significant improvements on psychopathological, cognitive, social, and clinical variables for patients suffering from schizophrenia, regardless of the type of molecule chosen. Full article

(This article belongs to the Special Issue New Insights in Psychiatric Disorder Psychopharmacology)

► Show Figures

Figure 1

Open AccessArticle

Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists

M. A. Alvarez-Mon

Cielo García-Montero

Oscar Fraile-Martinez

and

Brain Sci. 2023, 13(2), 333; https://doi.org/10.3390/brainsci13020333 - 15 Feb 2023

Viewed by 1215

Abstract

Major depressive disorder (MDD) is a complex psychiatric disorder that, presented alone or with other comorbidities, requires different adjustments of antidepressant treatments. Some investigations have demonstrated that psychoactive drugs, such as serotonin and norepinephrine reuptake inhibitors (SNRIs), can exert more effective and faster antidepressant effects than other common medications used, such as serotonin selective reuptake inhibitors (SSRIs), although these differences are still controversial. During the last five years, the SNRI duloxetine has shown favorable results in clinical practice for the treatment of MDD, anxiety, and fibromyalgia. Through an online self-completed survey, in the present article, we collected information from 163 psychiatrists regarding the use of duloxetine and its comparison with other psychiatric drugs, concerning psychiatrists’ knowledge and experience, as well as patients’ preferences, symptoms, and well-being. We discussed and contrasted physicians’ reports and the scientific literature, finding satisfactory concordances, and finally concluded that there is agreement regarding the use of duloxetine, not only due to its tolerability and effectiveness but also due to the wide variety of situations in which it can be used (e.g., somatic symptoms in fibromyalgia, diabetes) as it relieves neuropathic pain as well. Full article

(This article belongs to the Special Issue New Insights in Psychiatric Disorder Psychopharmacology)

► Show Figures

Figure 1

Review

Jump to: Research, Other

Open AccessReview

Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression

Ioana-Alexandra Dogaru

Maria Gabriela Puiu

Mirela Manea

and

Vlad Dionisie

Brain Sci. 2022, 12(10), 1403; https://doi.org/10.3390/brainsci12101403 - 18 Oct 2022

Viewed by 1437

Abstract

Since depression remains a major public health issue there is a constant need for new and more efficient therapeutic strategies based on the mechanisms involved in the aetiology of depression. Thus, the pathogenic link between depression and inflammation is considered to play a potential key role in the development of such therapies. This review summarizes the results of various pharmacological (non-steroidal anti-inflammatory drugs, aspirin, cyclooxygenase inhibitors, cytokine inhibitors, corticosteroids, statins, minocycline, N-acetyl cysteine, omega-3 fatty acids and probiotics) and non-pharmacological interventions (electroconvulsive therapy, physical exercise and psychological therapy) and outlines their efficacy and discusses potential challenges. Both conventional and non-conventional anti-inflammatory drugs showed promising results according to the specific group of patients. The pre-existing pro-inflammatory status was, in most cases, a predictor for clinical efficacy and, in some cases, a correlation between clinical improvement and changes in various biomarkers was found. Some of the non-pharmacological interventions (physical exercise and electroconvulsive therapy) have also showed beneficial effects for depressive patients with elevated inflammatory markers. Treatments with anti-inflammatory action may improve clinical outcomes in depression, at least for some categories of patients, thus opening the way for a future personalised approach to patients with unipolar depression regarding the inflammation-related mechanism. Full article

(This article belongs to the Special Issue New Insights in Psychiatric Disorder Psychopharmacology)

Open AccessReview

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

and

Brain Sci. 2022, 12(3), 382; https://doi.org/10.3390/brainsci12030382 - 12 Mar 2022

Cited by 7 | Viewed by 3907

Abstract

Eating disorders (EDs) are serious, life-threatening psychiatric conditions associated with physical and psychosocial impairment, as well as high morbidity and mortality. Given the chronic refractory nature of EDs and the paucity of evidence-based treatments, there is a pressing need to identify novel approaches for this population. The noncompetitive N-methyl-D-aspartate receptor (NMDAr) antagonist, ketamine, has recently been approved for treatment-resistant depression, exerting rapid and robust antidepressant effects. It is now being investigated for several new indications, including obsessive–compulsive, post-traumatic, and substance use disorder, and shows transdiagnostic potential for EDs, particularly among clinical nonresponders. Hence, the aim of this review is to examine contemporary findings on the treatment of EDs with ketamine, whether used as a primary, adjunctive, or combination psychopharmacotherapy. Avenues for future research are also discussed. Overall, results are encouraging and point to therapeutic value; however, are limited to case series and reports on anorexia nervosa. Further empirical research is thus needed to explore ketamine efficacy across ED subgroups, establish safety profiles and optimize dosing, and develop theory-driven, targeted treatment strategies at the individual patient level. Full article

(This article belongs to the Special Issue New Insights in Psychiatric Disorder Psychopharmacology)

Other

Jump to: Research, Review

Open AccessSystematic Review

A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia

and

Brain Sci. 2023, 13(2), 368; https://doi.org/10.3390/brainsci13020368 - 20 Feb 2023

Viewed by 862

Abstract

Cardiovascular disease (CVD), including heart disease and stroke, continues to be the leading cause of death worldwide. Patients with mental health disorders, including schizophrenia (SCZ) are known to have an increased risk for CVD. Given the association with metabolic syndrome, patients with SCZ are often prescribed metformin and statins but its impact remains unsatisfactory. The use of aspirin (ASA) to decrease cardiovascular risk in the general population has been thoroughly investigated and clear guidelines are currently in place. Since adjuvant treatment with ASA could possibly decrease CVD risk and mortality in SCZ, we conducted a systematic review of the literature to determine the state of the current literature on this subject. Our systematic review points to gaps in the literature on CVD prevention in SCZ and illustrates an obvious need for further research. Although several studies have shown increased CVD risk in SCZ, to date, no research has been conducted on the utilization of CVD preventative treatment such as ASA for SCZ. Full article

(This article belongs to the Special Issue New Insights in Psychiatric Disorder Psychopharmacology)

► Show Figures

Journal Menu

Journal Browser

Special Issue "New Insights in Psychiatric Disorder Psychopharmacology"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (5 papers)

Research

Review

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI